On April 27, Ge Longhui Pharmaceutical (688166.SH) released its report for the first quarter of 2024, achieving operating income of 340 million yuan, an increase of 11.54%; net profit attributable to shareholders of listed companies of 640.699 million yuan, a year-on-year decrease of 9.47%; net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 64.214,400 yuan, a year-on-year decrease of 7.89%; and basic earnings per share of 0.15 yuan.
博瑞医药(688166.SH)：一季度净利润6406.99万元 同比减少9.47%
Borui Pharmaceutical (688166.SH): Net profit of 640.69,900 yuan in the first quarter decreased by 9.47% year-on-year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.